Health Optimization Index
GHRP-2 (Pralmorelin)
- Nick’s assessment
- Experimental
- Research evidence
- C, mixed evidence
- Attention
- 25.0 / 100▲ Rising this week
BioHarmony score
GHRP-2 (pralmorelin) is a ghrelin-receptor peptide that drives a strong growth-hormone pulse, approved in Japan since 2004 as a diagnostic test. It is a stronger releaser than ipamorelin but less selective, raising cortisol, prolactin, and appetite by about 36 percent per Laferrere 2005, with no human body-composition outcome trials.
Read the full report Benefits, risks and practical guidance.
Read Nick’s assessment Why it earned this rating
GHRP-2 lands at Neutral because it pairs genuine strengths, a strong growth-hormone pulse and a one-of-a-kind diagnostic approval, with genuine weaknesses, lower selectivity and an empty adult-outcome file. If you want raw growth-hormone output and accept the appetite, cortisol, and prolactin off-targets, it does deliver a stronger release than ipamorelin, per Raun 1998. If you want a clean profile or evidence-backed fat loss, it is the wrong pick, and the better-supported path is tesamorelin. For any non-diagnostic use it is a research chemical, so sourcing and verification matter as much as the pharmacology. The two biggest real-world frictions are the hunger spike and the unregulated supply.
✅ Best for: Experienced peptide users who want a stronger growth-hormone pulse than ipamorelin and understand they are trading selectivity for it. Older adults with lower baseline growth-hormone output, who tend to respond more. People who will pair it with a short-acting GHRH peptide to exploit the documented synergy, per Bowers 2004. Anyone who can source verified pharmaceutical-grade material with a certificate of analysis and will monitor IGF-1, glucose, and the cortisol load. Users who already have training, protein, and sleep dialed in and want a closely tracked experiment rather than a proven staple.
❌ Avoid if: You have active or hormone-sensitive cancer, since growth-hormone and IGF-1 signaling can promote proliferation. You are pregnant or breastfeeding, with no safety data. You have uncontrolled diabetes or insulin resistance, because growth hormone opposes insulin. You are prone to high prolactin or cortisol problems, which GHRP-2 directly worsens, per Arvat 1997. You are trying to lose weight and cannot manage the roughly 36 percent appetite surge, per Laferrere 2005. You compete in tested sport, since it is banned at all times under WADA S2. You cannot verify source quality, because grey-market contamination may exceed the intrinsic risk. The honest trade with GHRP-2 is right there in the numbers. You buy a stronger growth-hormone pulse and the only regulator-validated credential in the whole GHRP class, and you pay for it with a 36 percent jump in hunger and a cortisol rise that ipamorelin simply does not have.Nick Urban, on the Raun 1998 head-to-head
Share your experience
Your answers are optional and help other readers — they never change my score. How community input works.
One step left: confirm it’s you
New voice here? We send a one-tap verification link so every entry comes from a real person. Signed-in members skip this.
Make a 12-month prediction Will it rise or fall in the Index?
Choose a direction and your confidence. Correct predictions earn leaderboard points.
Your prediction is final once submitted. We’ll check it in 12 months. See the leaderboard →